Form 8-K - Current report:
SEC Accession No. 0001193125-24-249124
Filing Date
2024-11-01
Accepted
2024-11-01 07:00:30
Documents
13
Period of Report
2024-10-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d891090d8k.htm   iXBRL 8-K 27258
  Complete submission text file 0001193125-24-249124.txt   149716

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tcrx-20241028.xsd EX-101.SCH 2845
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tcrx-20241028_lab.xml EX-101.LAB 17979
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tcrx-20241028_pre.xml EX-101.PRE 11255
15 EXTRACTED XBRL INSTANCE DOCUMENT d891090d8k_htm.xml XML 3637
Mailing Address 880 WINTER STREET WALTHAM MA 02451
Business Address 880 WINTER STREET WALTHAM MA 02451 857-399-9500
TScan Therapeutics, Inc. (Filer) CIK: 0001783328 (see all company filings)

EIN.: 825282075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40603 | Film No.: 241417007
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)